Acadia Healthcare Company, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHC research report →
Range $30 – $41
Price Chart
About the company
Acadia Healthcare Company, Inc. specializes in delivering a comprehensive range of behavioral health services, with its operations spanning the United States and Puerto Rico. Patients receive care in diverse environments, including acute inpatient psychiatric hospitals, specialized treatment facilities, long-term residential centers, and outpatient clinics.
- CEO
- Debra K. Osteen
- IPO
- 1994
- Employees
- 22,000
- HQ
- Franklin, TN, US
Get TickerSpark's AI analysis on ACHC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.22B
- P/E
- -3.01
- Fwd P/E
- 19.86
- PEG
- 0.00
- P/S
- 1.02
- P/B
- 1.69
- EV/EBITDA
- -8.83
- Div Yield
- 0.00%
- Gross Margin
- 16.10%
- Op Margin
- 9.77%
- Net Margin
- -33.07%
- ROE
- -57.05%
- ROIC
- 6.59%
Latest fiscal year · YoY change
- Revenue
- $3.31B+5.0%
- Gross Profit
- $583.44M-18.1%
- Op Income
- $387.96M
- Net Income
- $-1,102,772,000-531.4%
- EPS
- $-12.16-535.8%
- OCF Growth
- +1.7%
- FCF Growth
- +21.5%
- 52W High
- $39.70
- 52W Low
- $11.43
- 50D MA
- $31.15
- 200D MA
- $27.35
- Beta
- 0.63
- RSI (14)
- 52
- Avg Volume
- 1.82M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Acadia Healthcare beat expectations in Q3 2026, raised full-year guidance again, and pointed to accelerating contributions from new facilities, steady cash generation, and improving operating execution.· November 5, 2026
- Revenue, adjusted EBITDA, and adjusted EPS all came in above expectations, with same-facility revenue growth at the high end of guidance.
- The company raised full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and operating cash flow for the third consecutive quarter.
- New facilities are ramping faster than expected; management said all development-plan facilities are now open and highlighted 16 new facilities since early 2023.
- Cash flow remained strong, with $47 million of free cash flow in Q3 and $63 million of debt repayment, while net leverage was about 3.9x.
- Management reiterated confidence in the $200 million incremental adjusted EBITDA opportunity relative to 2025 and said about $60 million should come in 2027 versus 2026.
Q3 2026 revenue was $895 million, up 5.1% year over year. Same-facility revenue increased 5.2%, driven by 1.1% patient day growth and 4.0% growth in revenue per patient day. Consolidated adjusted EBITDA was $176.4 million, while same-facility adjusted EBITDA was $228.8 million, up 6.1% year over year. Revenue by segment included acute at $525 million, specialty at $136 million, RTC at $93 million, and CTC at $141 million. Operating cash flow was $98 million, capital expenditures were $51 million, and free cash flow was $47 million; debt was reduced by $63 million and net leverage was about 3.9x. Full-year 2026 guidance was raised to revenue of $3.44 billion-$3.46 billion, adjusted EBITDA of $615 million-$625 million, adjusted EPS of $1.70-$1.80, and operating cash flow of $375 million-$400 million. CapEx guidance was cut to $210 million-$230 million. Management said supplemental programs in Florida and Ohio under review could add more than $20 million in incremental EBITDA, but those are not in guidance.
Debbie Osteen framed the quarter as further evidence that the company is executing well on its turnaround and growth priorities. She emphasized stronger operating structures, faster licensing/accreditation/payer contracting for new sites, and a focus on quality, patient safety, and patient-centered care. Her tone was confident and optimistic, especially around continued volume growth, legacy-facility improvement, and the path to realizing the value of the company’s expanded bed base.
David Duckworth highlighted solid top-line and profitability trends, including $895 million of revenue, $176.4 million of adjusted EBITDA, and $47 million of free cash flow in the quarter. He noted same-facility adjusted EBITDA growth of 6.1%, debt paydown of $63 million, and net leverage of about 3.9x. He also explained that lower CapEx guidance to $210 million-$230 million mainly reflects reduced spend on de novo and joint venture projects, and he pointed to possible additional upside from Florida and Ohio supplemental programs worth more than $20 million in incremental EBITDA.
Analysts focused on how much growth remains in the recovery, whether the pace of new development should accelerate, and how much of the $60 million 2027 EBITDA bridge comes from startup losses fading versus underlying ramp. Management said the new facilities are ahead of schedule on licensure and accreditation, but they do not plan to factor new facilities into next year’s plan yet. Questions also covered CTC stabilization, commercial mix, length of stay, bad debts and denials, Medicaid policy risk, and legal expenses; management generally said trends are stable or improving, with New York Medicaid still a headwind but patient replacement running ahead of expectations.
The call showed broad operating momentum: revenue, EBITDA, EPS, and cash flow were all ahead of expectations, while same-facility growth stayed strong despite the New York Medicaid headwind. Management sounded increasingly confident that newer facilities are ramping faster, legacy sites still have room to improve, and 2027 could benefit from a large step-down in startup losses and continued occupancy gains.
The main risks discussed were still execution-related: New York Medicaid continues to pressure same-facility growth, startup facilities still generated about $45 million of losses this year, and several legal/government-related costs remain elevated and variable quarter to quarter. Management also left some of the larger upside items, including supplemental payment approvals and a fuller 2027 outlook, unresolved until later updates.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.5%
- Shares Outstanding
- 92.97M
- Float Shares
- 86.93M
of shares held by institutions
330 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ACHC, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 14.83M | ▼ 126.88K |
| Vanguard Group Inc | 9.35M | ▼ 66.09K |
| Vanguard Portfolio Management LLC | 5.61M | ▲ 243.19K |
| Dimensional Fund Advisors LP | 4.70M | ▲ 684.74K |
| Fmr LLC | 4.67M | ▼ 350.21K |
| Farallon Capital Management, L.L.C. | 4.61M | ▲ 387.60K |
| Dme Capital Management, LP | 4.40M | 0 |
| Vanguard Capital Management LLC | 4.21M | ▲ 203.59K |
| Abrams Bison Investments, LLC | 4.17M | 0 |
| State Street Corp | 3.83M | ▼ 58.28K |
| Carronade Capital Management, LP | 3.73M | ▼ 1.03M |
| Jefferies Financial Group Inc. | 3.70M | ▲ 98.17K |
Held by 391 ETFs
Biggest fund positions in ACHC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 26, 26 | Farley Brian | other | 1,770 |
| Jun 26, 26 | Farley Brian | other | 1,370 |
| May 1, 26 | Duckworth David M. | other | 0 |
| May 6, 26 | Fucci Michael | other | 6,331 |
| May 6, 26 | KELLY RALPH DAVID | other | 6,331 |
| May 6, 26 | Gregg Vicky B | other | 6,331 |
| May 6, 26 | Bernhard Jason | other | 5,124 |
| May 6, 26 | Bernhard Jason | other | 6,331 |
| May 6, 26 | GRIECO WILLIAM | other | 6,331 |
| May 6, 26 | Cancelmi Daniel J | other | 6,331 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACHC coverage
Recent articles, reports, and earnings notes.
No research on ACHC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACHC report →Most Small-Cap Value Funds Weight by Size. RZV Puts the Most Money in the Cheapest Stocks in the S&P 600
247wallst.com · Nov 17
What Makes Acadia Healthcare (ACHC) a Strong Momentum Stock: Buy Now?
zacks.com · Nov 10
Acadia Healthcare Company, Inc. (ACHC) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
Acadia Healthcare Company, Inc. (ACHC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
zacks.com · Nov 6
Acadia Healthcare Company, Inc. (ACHC) Hit a 52 Week High, Can the Run Continue?
zacks.com · Nov 6
Acadia Healthcare (NASDAQ:ACHC) Hits New 12-Month High on Strong Earnings
defenseworld.net · Nov 6
Acadia Healthcare Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.